Depression and anxiety in patients receiving an implantable cardioverter defibrillator with or without cardiac resynchronization therapy
Abstract
Implantable cardioverter defibrillators (ICDs) represent an established therapeutic strategy for the prevention of sudden cardiac death and reduction of mortality in high-risk patients, while ICDs with cardiac resynchronization therapy defibrillators improve morbidity, quality of life, and mortality in eligible patients with heart failure who are on optimal medical therapy. However, these devices may adversely affect the patients’ psychological status after the delivery of shock therapies or even because of the fear of impending therapy. On the other hand, the potential of effective treatment of malignant arrhythmias may provide a ‘safety’ sensation in most treated patients without significant impairment in the quality of life during periods of clinical stability. During the past few years, an increasing number of reports have investigated psychological distress, including depression and anxiety status in ICD/cardiac resynchronization therapy defibrillator recipients. However, heterogeneous results have been reported while data on the variation of these psychological indexes over time in implanted patients are quite limited. Several intrinsic and extrinsic factors affect the psychological status of these patients while variations of these disturbances in specific populations are evident. Factors that seem to be associated with a greater risk for depression and anxiety in this setting include female gender, younger age, and device shock therapies. Moreover, depression and anxiety may have an adverse impact on patients’ clinical outcomes exacerbating heart failure and increasing the arrhythmic risk. In this brief review article, we provide a concise and critical overview of the current literature on this topic, and we also discuss unresolved and conflicting issues delineating future perspectives.
References
Goldenberg I, Huang DT, Nielsen JC. The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome. Eur Heart J 2020; 41: 2003−2011.
Atreya AR, Cook JR, Lindenauer PK. Complications arising from cardiac implantable electrophysiological devices: review of epidemiology, pathogenesis and prevention for the clinician. Postgrad Med 2016; 128: 223−230.
Tarakji KG, Korantzopoulos P, Philippon F, et al. Infectious consequences of hematoma from cardiac implantable electronic device procedures and the role of the antibiotic envelope: a WRAP-IT trial analysis. Heart Rhythm 2021; 18: 2080−2086.
Rao P, Faddis M. Cardiac resynchronisation therapy: current indications, management and basic troubleshooting. Heart 2017; 103: 2000−2007.
Nakai T, Ikeya Y, Kogawa R, et al. Cardiac resynchronization therapy: current status and near-future prospects. J Cardiol 2022; 79: 352−357.
McAlister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 381−390.
Chen S, Yin Y, Krucoff MW. Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. Europace 2012; 14: 1602−1607.
Tomzik J, Koltermann KC, Zabel M, et al. Quality of life in patients with an implantable cardioverter defibrillator: a systematic review. Front Cardiovasc Med 2015; 2: 34.
McCready MJ, Exner DV. Quality of life and psychological impact of implantable cardioverter defibrillators: focus on randomized controlled trial data. Card Electrophysiol Rev 2003; 7: 63−70.
Francis J, Johnson B, Niehaus M. Quality of life in patients with implantable cardioverter defibrillators. Indian Pacing Electrophysiol J 2006; 6: 173−181.
Burke JL, Hallas CN, Clark-Carter D, et al. The psychosocial impact of the implantable cardioverter defibrillator: a meta-analytic review. Br J Health Psychol 2003; 8: 165−178.
Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res 2011; 71: 223−231.
Oshvandi K, Khatiban M, Ghanei Gheshlagh R, et al. The prevalence of depression in patients living with implantable cardioverter defibrillator: a systematic review and meta-analysis. Ir J Med Sci 2020; 189: 1243−1252.
Amiaz R, Asher E, Rozen G, et al. Do implantable cardioverter defibrillators contribute to new depression or anxiety symptoms? A retrospective study. Int J Psychiatry Clin Pract 2016; 20: 101−105.
Habibović M, Denollet J, Pedersen SS, et al. Posttraumatic stress and anxiety in patients with an implantable cardioverter defibrillator: trajectories and vulnerability factors. Pacing Clin Electrophysiol 2017; 40: 817−823.
Ghezzi ES, Sharman RLS, Selvanayagam JB, et al. Burden of mood symptoms and disorders in implantable cardioverter defibrillator patients: a systematic review and meta-analysis of 39954 patients. Europace 2023; 25: euad130.
Frydensberg VS, Johansen JB, Möller S, et al. Anxiety and depression symptoms in Danish patients with an implantable cardioverter-defibrillator: prevalence and association with indication and sex up to 2 years of follow-up (data from the national DEFIB-WOMEN study). Europace 2020; 22: 1830−1840.
Pedersen SS, Wehberg S, Nielsen JC, et al. Patients with an implantable cardioverter defibrillator at risk of poorer psychological health during 24 months of follow-up (results from the Danish national DEFIB-WOMEN study). Gen Hosp Psychiatry 2023; 80: 54−61.
Van Den Broek KC, Habibović M, Pedersen SS. Emotional distress in partners of patients with an implantable cardioverter defibrillator: a systematic review and recommendations for future research. Pacing Clin Electrophysiol 2010; 33: 1442−1450.
Rottmann N, Skov O, Andersen CM, et al. Psychological distress in patients with an implantable cardioverter defibrillator and their partners. J Psychosom Res 2018; 113: 16−21.
Köbe J, Hucklenbroich K, Geisendörfer N, et al. Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. Clin Res Cardiol 2017; 106: 317−321.
Pedersen SS, Carter N, Barr C, et al. Quality of life, depression, and anxiety in patients with a subcutaneous versus transvenous defibrillator system. Pacing Clin Electrophysiol 2019; 42: 1541−1551.
Thylén I, Dekker RL, Jaarsma T, et al. Characteristics associated with anxiety, depressive symptoms, and quality-of-life in a large cohort of implantable cardioverter defibrillator recipients. J Psychosom Res 2014; 77: 122−127.
Wong MF. Factors associated with anxiety and depression among patients with implantable cardioverter defibrillator. J Clin Nurs 2017; 26: 1328−1337.
Tripp C, Huber NL, Kuhl EA, et al. Measuring ICD shock anxiety: status update on the Florida Shock Anxiety Scale after over a decade of use. Pacing Clin Electrophysiol 2019; 42: 1294−1301.
Perini AP, Kutyifa V, Veazie P, et al. Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: a MADIT-RIT substudy. Am Heart J 2017; 189: 75−84.
Pedersen SS, Nielsen JC, Wehberg S, et al. New onset anxiety and depression in patients with an implantable cardioverter defibrillator during 24 months of follow-up (data from the national DEFIB-WOMEN study). Gen Hosp Psychiatry 2021; 72: 59−65.
Shi S, Liu T, Liang J, et al. Depression and risk of sudden cardiac death and arrhythmias: a meta-analysis. Psychosom Med 2017; 79: 153−161.
Habibović M, Pedersen SS, van den Broek KC, et al. Anxiety and risk of ventricular arrhythmias or mortality in patients with an implantable cardioverter defibrillator. Psychosom Med 2013; 75: 36−41.
Francis JL, Weinstein AA, Krantz DS, et al. Association between symptoms of depression and anxiety with heart rate variability in patients with implantable cardioverter defibrillators. Psychosom Med 2009; 71: 821−827.
Shalaby AA, Brumberg GE, Pointer L, et al. Depression and outcome among veterans with implantable cardioverter defibrillators with or without cardiac resynchronization therapy capability. Pacing Clin Electrophysiol 2014; 37: 994−1001.
Andersen CM, Theuns DAMJ, Johansen JB, et al. Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter defibrillator: 7 years’ follow-up of the MIDAS cohort. Gen Hosp Psychiatry 2020; 66: 154−160.
Mastenbroek MH, Versteeg H, Jordaens L, et al. Ventricular tachyarrhythmias and mortality in patients with an implantable cardioverter defibrillator: impact of depression in the MIDAS cohort. Psychosom Med 2014; 76: 58−65.
Habibović M, Pedersen SS, van den Broek KC, et al. Anxiety and risk of ventricular arrhythmias or mortality in patients with an implantable cardioverter defibrillator. Psychosom Med 2013; 75: 36−41.
Whang W, Albert CM, Sears SF Jr, et al. Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol 2005; 45: 1090−1095.
Bundgaard JS, Thune JJ, Nielsen JC, et al. The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. Europace 2019; 21: 900−908.
Johansen JB, Pedersen SS, Spindler H, et al. Symptomatic heart failure is the most important clinical correlate of impaired quality of life, anxiety, and depression in implantable cardioverter-defibrillator patients: a single-centre, cross-sectional study in 610 patients. Europace 2008; 10: 545−551.
Kindermann I, Wedegärtner SM, Bernhard B, et al. Changes in quality of life, depression, general anxiety, and heart-focused anxiety after defibrillator implantation. ESC Heart Fail 2021; 8: 2502−2512.
Cleland JG, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J 2009; 157: 457−466.
Knackstedt C, Arndt M, Mischke K, et al. Depression, psychological distress, and quality of life in patients with cardioverter defibrillator with or without cardiac resynchronization therapy. Heart Vessels 2014; 29: 364−374.
Duncker D, Friedel K, König T, et al. Cardiac resynchronization therapy improves psycho-cognitive performance in patients with heart failure. Europace 2015; 17: 1415−1421.
Shalaby AA, Brumberg GE, Pointer L, et al. Depression and outcome among veterans with implantable cardioverter defibrillators with or without cardiac resynchronization therapy capability. Pacing Clin Electrophysiol 2014; 37: 994−1001.
Ford J, Sears S, Ramza B, et al. The Registry Evaluating Functional Outcomes of Resynchronization Management (REFORM): quality of life and psychological functioning in patients receiving cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2014; 25: 43−51.
Freedenberg V, Thomas SA, Friedmann E. Anxiety and depression in implanted cardioverter-defibrillator recipients and heart failure: a review. Heart Fail Clin 2011; 7: 59−68.
Ford J, Rosman L, Wuensch K, et al. Cognitive-behavioral treatment of posttraumatic stress in patients with implantable cardioverter defibrillators: results from a randomized controlled trial. J Trauma Stress 2016; 29: 388−392.
Schulz SM, Ritter O, Zniva R, et al. Efficacy of a web-based intervention for improving psychosocial well-being in patients with implantable cardioverter-defibrillators: the randomized controlled ICD-FORUM trial. Eur Heart J 2020; 41: 1203−1211.
Kikkenborg Berg S, Caspar Thygesen L, Hastrup Svendsen J, et al. Anxiety predicts mortality in ICD patients: results from the cross-sectional national CopenHeartICD survey with register follow-up. Pacing Clin Electrophysiol 2014; 37: 1641−1650.
Yin FH, Fan CL, Guo YY, et al. The impact of gender difference on clinical and echocardiographic outcomes in patients with heart failure after cardiac resynchronization therapy: a systematic review and meta-analysis. PLoS One 2017; 12: e0176248.
京公网安备11010802044758号